These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 800772)

  • 21. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans.
    Whelan WL
    Crit Rev Microbiol; 1987; 15(1):45-56. PubMed ID: 3319420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New heterocyclic derivatives of benzimidazole with germicidal activity. IV--In vivo anticandida activity of 5-fluoro-2-(5'-nitro-2'-furyl) benzimidazole (F-O-NO2).
    Pedini M; Bistocchi GA; De Meo G; Ricci A; Jacquignon P; Riccardi C; Bastianini L; Sposini T
    Farmaco Sci; 1987 Jul; 42(7):541-7. PubMed ID: 3311805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo.
    Sneller MR; Hariri A; Sorenson WG; Larsh HW
    Antimicrob Agents Chemother; 1977 Sep; 12(3):390-4. PubMed ID: 334065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Sensitivity in vitro of opportunist yeasts (Candida albicans and Torulopsis glabrata) to flucytosine and concordance curves (author's transl)].
    Slim A; Bergogne-Berezin E; Courtoux D
    Ann Biol Clin (Paris); 1978; 36(2):69-74. PubMed ID: 358866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergism of polyene antibiotics with 5-fluorocytosine.
    Polak A
    Chemotherapy; 1978; 24(1):2-16. PubMed ID: 338264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Concentration-contact time relationship in the effect of antimycotic drug combinations (clotrimazole, nystatin, 5-fluorocytosine) and the effect of increasing and decreasing antimycotic drug concentrations on Candida albicans].
    Rumler W; Heins S
    Mykosen; 1985 May; 28(5):251-7. PubMed ID: 3892290
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro antifungal activity of eugenol and vanillin against Candida albicans and Cryptococcus neoformans.
    Boonchird C; Flegel TW
    Can J Microbiol; 1982 Nov; 28(11):1235-41. PubMed ID: 6758923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients.
    Paniagua GL; Monroy E; Negrete E; Vaca S
    Rev Latinoam Microbiol; 2002; 44(2):65-8. PubMed ID: 17063773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy of deep-seated fungal infections with 5-fluorocytosine.
    Firkin FC
    Aust N Z J Med; 1974 Oct; 4(5):462-7. PubMed ID: 4616675
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans.
    Ghannoum MA; Fu Y; Ibrahim AS; Mortara LA; Shafiq MC; Edwards JE; Criddle RS
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2459-65. PubMed ID: 8585726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenicity in mice of strains of Candida albicans with different in vitro sensitivity to 5-fluorocytosine.
    Persson M; Winblad B; Anséhn S; Schönebeck J
    Scand J Infect Dis; 1978; 10(1):87-90. PubMed ID: 345424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryptococcal meningitis treated with 5-fluorocytosine and amphotericin B.
    Halkin H; Ravid M; Zulman J; Reichert N
    Isr J Med Sci; 1974 Sep; 10(9):1148-52. PubMed ID: 4611967
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanisms of synergistic interactions between amphotericin B and flucytosine.
    Beggs WH
    J Antimicrob Chemother; 1986 Apr; 17(4):402-4. PubMed ID: 3519560
    [No Abstract]   [Full Text] [Related]  

  • 34. [Further experimental data on clotrimazole: effectiveness against Cryptococcus neoformans, Sporothrix schenkii and Blastomyces dermatitidis Gilchrist].
    Barfuss T; Seeliger HP; Plempel M
    Mykosen; 1975 May; 18(5):221-32. PubMed ID: 1099444
    [No Abstract]   [Full Text] [Related]  

  • 35. Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies.
    Galgiani JN
    Rev Infect Dis; 1990; 12 Suppl 3():S272-5. PubMed ID: 2184504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-Fluorocytosine and Candida yeasts.
    Fabbri A; Tacchella A; Belli ML; Toriello E
    Chemioterapia; 1987 Feb; 6(1):8-11. PubMed ID: 3549011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
    Poon M; Cronin DC; Wormser GP; Bottone EJ
    Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.
    Mitsuyama J; Nomura N; Hashimoto K; Yamada E; Nishikawa H; Kaeriyama M; Kimura A; Todo Y; Narita H
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1318-24. PubMed ID: 18227186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro studies with combinations of 5-fluorocytosine and amphotericin B.
    Shadomy S; Wagner G; Espinel-Ingroff E; Davis BA
    Antimicrob Agents Chemother; 1975 Aug; 8(2):117-21. PubMed ID: 1101814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine.
    Block ER; Jennings AE; Bennett JE
    Antimicrob Agents Chemother; 1973 Oct; 4(4):392-5. PubMed ID: 4598611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.